Literature DB >> 23260322

Adenosine A1 receptor agonist, N6-cyclohexyladenosine, protects myelin and induces remyelination in an experimental model of rat optic chiasm demyelination; electrophysiological and histopathological studies.

Ali Akbar Asghari1, Mahnaz Azarnia, Javad Mirnajafi-Zadeh, Mohammad Javan.   

Abstract

Chronic demyelinated lesions and subsequent functional impairment are resulted from eventual failure of remyelination process as seen in multiple sclerosis. Activation of adenosine A1 receptor is reported to be effective on neural stem cells (NSCs) proliferation and oligodendrocytes differentiation. Therefore, this study attempted to investigate the effect of A1 receptor agonist N6-cyclohexyladenosine (CHA), on lysolecithin (LPC) induced demyelination and remyelination in rat optic chiasm. The experiments were carried out on male Wistar rats using visual evoked potential recording, myelin staining by Luxol fast blue and histological evaluation of demyelinated and remyelinated axons within the area of lesion. CHA was administrated i.c.v. during demyelination or remyelination phases. As revealed by myelin staining, the most extent of demyelination occurred at 7th day post-lesion (dpl 7), but gradually myelination was restored toward control during days 14-28. VEP P1-latency and P1-N1 amplitude showed widespread demyelination on dpl 7 and 14 which consequently was reversed during days 14-28 post lesion. I.c.v. treatment of animals with CHA during demyelination phase (days 0-13) reduced the extent of demyelination. During remyelination phase (days 14-28), CHA was able to increase remyelination in both electrophysiological and histopathological studies. The effects of CHA seem to be due to its protective effect on myelinating cells and its regenerative effect through potentiating endogenous neural progenitors.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23260322     DOI: 10.1016/j.jns.2012.11.008

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

1.  Adenosine Promotes the Recovery of Mice from the Cuprizone-Induced Behavioral and Morphological Changes while Effecting on Microglia and Inflammatory Cytokines in the Brain.

Authors:  Jinling Zhang; Liu Yang; Zeman Fang; Jiming Kong; Qingjun Huang; Haiyun Xu
Journal:  J Neuroimmune Pharmacol       Date:  2018-08-01       Impact factor: 4.147

Review 2.  Purinergic signaling in oligodendrocyte development and function.

Authors:  Taylor G Welsh; Sarah Kucenas
Journal:  J Neurochem       Date:  2018-03-25       Impact factor: 5.372

Review 3.  Oligodendrocyte precursor cell maturation: role of adenosine receptors.

Authors:  Federica Cherchi; Anna Maria Pugliese; Elisabetta Coppi
Journal:  Neural Regen Res       Date:  2021-09       Impact factor: 5.135

4.  Purinergic Receptor Expression and Potential Association with Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cell Development.

Authors:  Shirin Kashfi; Maryam Peymani; Kamran Ghaedi; Hossein Baharvand; Mohammad Hossein Nasr-Esfahani; Mohammad Javan
Journal:  Cell J       Date:  2017-08-19       Impact factor: 2.479

Review 5.  The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis.

Authors:  Eduardo Duarte-Silva; Henning Ulrich; Ágatha Oliveira-Giacomelli; Hans-Peter Hartung; Sven G Meuth; Christina Alves Peixoto
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

6.  Effects of Levothyroxine on Visual Evoked Potential Impairment Following Local Injections of Lysolecithin into the Rat Optic Chiasm.

Authors:  Cobra Payghani; Fatemeh Khani; Aryan Rafieezadeh; Parham Reisi; Hojjatallah Alaei; Bahman Rashidi
Journal:  Int J Prev Med       Date:  2018-02-08

7.  The Effect of Levothyroxine on Serum Levels of Interleukin 10 and Interferon-gamma in Rat Model of Multiple Sclerosis.

Authors:  Cobra Payghani; Fatemeh Khani; Aryan Rafiee Zadeh; Parham Reisi; Hojjatallah Alaei; Bahman Rashidi
Journal:  Adv Biomed Res       Date:  2017-09-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.